Kestra Medical Technologies (NASDAQ:KMTS) Director Kevin Reilly Sells 2,932 Shares

Key Points

• Director Kevin Reilly sold 2,932 KMTS shares for approximately $73,681 at an average price of $25.13, reducing his holdings by 35.33% to 5,368 shares. The sale was reportedly made to cover tax withholding on vested equity awards.
• Kestra Medical Technologies’ shares recently traded at $23.57, while the company reported a quarterly loss of $0.67 per share—worse than analysts’ expected loss of $0.59—on revenue of $28.64 million.
• Analyst sentiment is mixed, with an overall “Hold” rating and an average price target of $28.14; ratings range from “Sell” to “Buy,” including a $32 target from BTIG Research.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) Director Kevin Reilly sold 2,932 shares of Kestra Medical Technologies stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $25.13, for a total transaction of $73,681.16. Following the transaction, the director owned 5,368 shares in the company, valued at $134,897.84. This represents a 35.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Performance

NASDAQ KMTS traded down $0.50 on Thursday, hitting $23.57. 310,496 shares of the company traded hands, compared to its average volume of 240,413. The business's 50 day moving average price is $25.42 and its 200-day moving average price is $22.71. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $30.00. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -9.74 and a beta of 0.62.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Institutional Trading of Kestra Medical Technologies

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. increased its stake in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after acquiring an additional 474 shares during the period. BNP Paribas Financial Markets grew its position in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock worth $65,000 after purchasing an additional 1,638 shares during the period. Daiwa Securities Group Inc. acquired a new position in shares of Kestra Medical Technologies in the 4th quarter valued at about $72,000. Brown Brothers Harriman & Co. grew its holdings in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company's stock worth $74,000 after acquiring an additional 656 shares during the period. Finally, New York State Common Retirement Fund acquired a new position in Kestra Medical Technologies in the second quarter valued at approximately $93,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Weiss Ratings lowered Kestra Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday, August 31st. BTIG Research reissued a "buy" rating and issued a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, September 2nd. Wall Street Zen raised shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a report on Monday, August 10th. They set an "overweight" rating and a $30.00 price objective on the stock. Finally, Oppenheimer began coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a "market perform" rating on the stock. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $28.14.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.